Register entry
La Jolla Pharmaceutical Company
- Registered sites
- 0
- Drug products
- 5
- Live patents
- 33
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
33Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| GIAPREZA | ANGIOTENSIN II ACETATE | Dec 2029 |
| GIAPREZA | ANGIOTENSIN II ACETATE | Nov 2030 |
| GIAPREZA | ANGIOTENSIN II ACETATE | Jul 2031 |
| GIAPREZA | ANGIOTENSIN II ACETATE | Dec 2034 |
| GIAPREZA | ANGIOTENSIN II ACETATE | Jan 2037 |
Catalogue
Marketed products
5Showing 5 of 5.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Giapreza | angiotensin II | INJECTION | NDA |
| Giapreza | angiotensin II | INJECTION | NDA |
| NUZOLVENCE | zoliflodacin | FOR SUSPENSION | NDA |
| Xacduro | sulbactam and durlobactam | KIT | NDA |
| ZEVTERA | ceftobiprole medocaril sodium | INJECTION, POWDER, FOR SOLUTION | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.